Condition

Biochemical Recurrence of Malignant Neoplasm of Prostate

ClinicalTrials.gov condition label

Clinical trials9
Recruiting4
Common interventions10
Lead sponsors shown8

Clinical trials

9 shown
Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.NCT07483658 · 2026-05-13
RECRUITING
A Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA-ligand PETNCT06859203 · 2025-03-01
RECRUITING
Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate CancerNCT06657131 · 2024-11-01
RECRUITING
PROCARE - PROstate Cancer Real World Evidence RegistryNCT06835218 · 2024-01-29
RECRUITING
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate CancerNCT06235099 · 2024-04-01
COMPLETED
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese PatientsNCT05847348 · 2023-07-19
UNKNOWN
SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical ProstatectomyNCT04931979 · 2022-10-20
UNKNOWN
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)NCT05407311 · 2022-09-19
COMPLETED
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)NCT05249127 · 2022-04-11
COMPLETED

Trial status mix

RECRUITING4
COMPLETED3
UNKNOWN2

Phase mix

PHASE23
PHASE32
NA1
PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.